The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42.
Glutamate transporters are involved in the maintenance of synaptic glutamate concentrations. Because of its potential neurotoxicity, clearance of glutamate from the synaptic cleft may be critical for neuronal survival. Inhibition of glutamate uptake from the synapse has been implicated in several neurodegenerative disorders. In particular, glutamate uptake is inhibited in Alzheimer's disease (AD); however, the mechanism of decreased transporter activity is unknown. Oxidative damage in brain is implicated in models of neurodegeneration, as well as in AD. Glutamate transporters are inhibited by oxidative damage from reactive oxygen species and lipid peroxidation products such as 4-hydroxy-2-nonenal (HNE). Therefore, we have investigated a possible connection between the oxidative damage and the decreased glutamate uptake known to occur in AD brain. Western blots of immunoprecipitated HNE-immunoreactive proteins from the inferior parietal lobule of AD and control brains suggest that HNE is conjugated to GLT-1 to a greater extent in the AD brain. A similar analysis of beta amyloid (Abeta)-treated synaptosomes shows for the first time that Abeta1-42 also increases HNE conjugation to the glutamate transporter. Together, our data provide a possible link between the oxidative damage and neurodegeneration in AD, and supports the role of excitotoxicity in the pathogenesis of this disorder. Furthermore, our data suggests that Abeta may be a possible causative agent in this cascade.
Lauderback
C M
CM
Department of Chemistry, and Center of Membrane Sciences, University of Kentucky, Lexington, Kentucky, USA.
Hackett
J M
JM
Huang
F F
FF
Keller
J N
JN
Szweda
L I
LI
Markesbery
W R
WR
Butterfield
D A
DA
D018528:ATP-Binding Cassette Transporters / Q000187:drug effects / Q000378:metabolism*; D000368:Aged; D000447:Aldehydes / Q000494:pharmacology*; D027322:Amino Acid Transport System X-AG; D016229:Amyloid beta-Peptides / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D002540:Cerebral Cortex / Q000378:metabolism; D003432:Cross-Linking Reagents / Q000494:pharmacology; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D008297:Male; D009457:Neuroglia / Q000378:metabolism* / Q000473:pathology; D009929:Organ Size; D010084:Oxidation-Reduction; D010296:Parietal Lobe / Q000378:metabolism* / Q000473:pathology; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D012016:Reference Values; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism
D018528:ATP-Binding Cassette Transporters; D000447:Aldehydes; D027322:Amino Acid Transport System X-AG; D016229:Amyloid beta-Peptides; D003432:Cross-Linking Reagents; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D018698:Glutamic Acid; C027576:4-hydroxy-2-nonenal